

# Colorectal Cancer - Pipeline Review, H2 2018

<https://marketpublishers.com/r/C17E15E283FEN.html>

Date: December 2018

Pages: 2548

Price: US\$ 2,500.00 (Single User License)

ID: C17E15E283FEN

## Abstracts

Colorectal Cancer - Pipeline Review, H2 2018

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 28, 157, 178, 17, 204, 39 and 13 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 35 and 5 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Colorectal Cancer - Overview

Colorectal Cancer - Therapeutics Development

Colorectal Cancer - Therapeutics Assessment

Colorectal Cancer - Companies Involved in Therapeutics Development

Colorectal Cancer - Drug Profiles

Colorectal Cancer - Dormant Projects 2439

Colorectal Cancer - Discontinued Products 2462

Colorectal Cancer - Product Development Milestones 2468

Appendix 2479

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Colorectal Cancer, H2 2018  
Number of Products under Development by Companies, H2 2018  
Number of Products under Development by Universities/Institutes, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Universities/Institutes, H2 2018  
Number of Products by Stage and Target, H2 2018  
Number of Products by Stage and Mechanism of Action, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2018  
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2018  
Colorectal Cancer - Pipeline by 4SC AG, H2 2018  
Colorectal Cancer - Pipeline by Aadi Bioscience Inc, H2 2018  
Colorectal Cancer - Pipeline by AB Science SA, H2 2018  
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2018  
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2018  
Colorectal Cancer - Pipeline by Abpro, H2 2018  
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018  
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2018  
Colorectal Cancer - Pipeline by ADC Therapeutics SA, H2 2018  
Colorectal Cancer - Pipeline by Adhera Therapeutics, H2 2018  
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2018  
Colorectal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2018  
Colorectal Cancer - Pipeline by Advanced BioDesign, H2 2018  
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018  
Colorectal Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018  
Colorectal Cancer - Pipeline by Agenus Inc, H2 2018  
Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2018  
Colorectal Cancer - Pipeline by Alkermes Plc, H2 2018  
Colorectal Cancer - Pipeline by Alligator Bioscience AB, H2 2018  
Colorectal Cancer - Pipeline by Allinky Biopharma SL, H2 2018  
Colorectal Cancer - Pipeline by Almac Discovery Ltd, H2 2018  
Colorectal Cancer - Pipeline by Alpine Immune Sciences Inc, H2 2018  
Colorectal Cancer - Pipeline by ALX Oncology Inc, H2 2018

Colorectal Cancer - Pipeline by Amarin Corp Plc, H2 2018  
Colorectal Cancer - Pipeline by amcure GmbH, H2 2018  
Colorectal Cancer - Pipeline by Amgen Inc, H2 2018  
Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2018  
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2018  
Colorectal Cancer - Pipeline by Aphios Corp, H2 2018  
Colorectal Cancer - Pipeline by Apogenix AG, H2 2018  
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2018  
Colorectal Cancer - Pipeline by Arcus Biosciences Inc, H2 2018  
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2018  
Colorectal Cancer - Pipeline by Arvinas Inc, H2 2018  
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2018  
Colorectal Cancer - Pipeline by Ascelia Pharma AB, H2 2018  
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018  
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2018  
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018  
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2018  
Colorectal Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018  
Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2018  
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2018  
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018  
Colorectal Cancer - Pipeline by Batu Biologics Inc, H2 2018  
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2018  
Colorectal Cancer - Pipeline by Bayer AG, H2 2018  
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Colorectal Cancer, H2 2018  
Number of Products under Development by Companies, H2 2018  
Number of Products under Development by Universities/Institutes, H2 2018  
Number of Products by Top 10 Targets, H2 2018  
Number of Products by Stage and Top 10 Targets, H2 2018  
Number of Products by Top 10 Mechanism of Actions, H2 2018  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018  
Number of Products by Top 10 Routes of Administration, H2 2018  
Number of Products by Stage and Top 10 Routes of Administration, H2 2018  
Number of Products by Top 10 Molecule Types, H2 2018  
Number of Products by Stage and Top 10 Molecule Types, H2 2018

### COMPANIES MENTIONED

3SBio Inc  
3-V Biosciences Inc  
4SC AG  
Aadi Bioscience Inc  
AB Science SA  
AbbVie Inc  
AbGenomics International Inc  
Abpro  
Aclaris Therapeutics Inc  
Adamed Sp z oo  
ADC Therapeutics SA  
Adhera Therapeutics  
Aduro BioTech Inc  
Advanced Accelerator Applications SA  
Advanced BioDesign  
Advenchen Laboratories LLC  
Agency for Science, Technology and Research  
Agenus Inc  
AlfaSigma SpA  
Alkermes Plc  
Alligator Bioscience AB



Allinky Biopharma SL  
Almac Discovery Ltd  
Alpine Immune Sciences Inc  
ALX Oncology Inc  
Amarin Corp Plc  
amcure GmbH  
Amgen Inc  
APEIRON Biologics AG  
Apexigen Inc  
Aphios Corp  
Apogenix AG  
Aposense Ltd  
Arcus Biosciences Inc  
Array BioPharma Inc  
Arvinas Inc  
Asana BioSciences LLC  
Ascelia Pharma AB  
Aslan Pharmaceuticals Pte Ltd  
Astellas Pharma Inc  
Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Aurigene Discovery Technologies Ltd  
Aurobindo Pharma Ltd  
B Cell Design SAS  
Basilea Pharmaceutica Ltd  
Batu Biologics Inc  
Bavarian Nordic A/S  
Bayer AG  
BeiGene Ltd  
Beijing Hanmi Pharmaceutical Co Ltd  
BeyondSpring Inc  
Biocon Ltd  
BioLineRx Ltd  
Bionomics Ltd  
Bionovis SA  
Biosceptre International Ltd  
BioXpress Therapeutics SA  
Boehringer Ingelheim GmbH  
Boston Biomedical Inc

Bristol-Myers Squibb Co  
Calithera Biosciences Inc  
CanBas Co Ltd  
Cancer Prevention Pharmaceuticals Inc  
Canget BioTekpharma LLC  
Cantargia AB  
Carna Biosciences Inc  
CaroGen Corp  
CBT Pharmaceuticals Inc  
CCRP Therapeutics GmbH  
Celgene Corp  
Celldex Therapeutics Inc  
Cellestar Biosciences Inc  
Celleron Therapeutics Ltd  
Cellestia Biotech AG  
Cellix Bio Pvt Ltd  
Celltrion Inc  
Celyad SA  
Checkmate Pharmaceuticals Inc  
Chengdu Kanghong Pharmaceuticals Group Co  
Chiome Bioscience Inc  
Chipscreen Biosciences Ltd  
ChoDang Pharm Co Ltd  
Chong Kun Dang Pharmaceutical Corp  
Chugai Pharmaceutical Co Ltd  
Cinnagen Co  
Cleveland BioLabs Inc  
COARE Biotechnology Inc  
Compugen Ltd  
Conatus Pharmaceuticals Inc  
Corvus Pharmaceuticals Inc  
Cotinga Pharmaceuticals Inc  
Cytlimic Inc  
Daiichi Sankyo Co Ltd  
Deciphera Pharmaceuticals LLC  
Dr. Reddy's Laboratories Ltd  
eFFECTOR Therapeutics Inc  
Eisai Co Ltd  
Eli Lilly and Co

Endor Technologies SL  
Enochian Biosciences Inc  
EntreChem SL  
Enzene Biosciences Ltd  
Enzo Biochem Inc  
EpiThany Inc  
Etubics Corp  
Evelo Biosciences Inc  
Exelixis Inc  
Exicure Inc  
F. Hoffmann-La Roche Ltd  
Faron Pharmaceuticals Oy  
Fate Therapeutics Inc  
FLX Bio Inc  
Fog Pharmaceuticals Inc  
Forbuis  
Formosa Laboratories Inc  
Forty Seven Inc  
Fresenius SE & Co KGaA  
F-star Biotechnology Ltd  
Fujifilm Holdings Corporation  
Fusion Antibodies plc

## I would like to order

Product name: Colorectal Cancer - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/C17E15E283FEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C17E15E283FEN.html>